Cargando…

A prospective, randomised, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: effects of adalimumab treatment on synovial tissue

OBJECTIVE: To determine which of the changes in synovial tissue correlates best with clinical response associated with effective therapy (adalimumab) to facilitate the planning of future studies with therapeutic agents for psoriatic arthritis (PsA). METHODS: A total of 24 patients with active PsA we...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Kuijk, A W R, Gerlag, D M, Vos, K, Wolbink, G, de Groot, M, de Rie, M A, Zwinderman, A H, Dijkmans, B A C, Tak, P P
Formato:	Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2008
Materias:	Clinical and Epidemiological Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2703703/ https://www.ncbi.nlm.nih.gov/pubmed/18647851 http://dx.doi.org/10.1136/ard.2008.091389

Ejemplares similares

Soluble Biomarkers of Cartilage and Bone Metabolism in Early Proof of Concept Trials in Psoriatic Arthritis: Effects of Adalimumab Versus Placebo
por: van Kuijk, Arno W. R., et al.
Publicado: (2010)

Alefacept treatment in psoriatic arthritis: reduction of the synovial inflammatory infiltrate and improvement of clinical signs of arthritis
por: Kraan, MC, et al.
Publicado: (2002)

Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)
por: Mease, P J, et al.
Publicado: (2008)

Impact of Adalimumab Treatment on Interleukin-17 and Interleukin-17 Receptor Expression in Skin and Synovium of Psoriatic Arthritis Patients with Mild Psoriasis
por: Bolt, Janne W., et al.
Publicado: (2022)

Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response
por: Thurlings, R M, et al.
Publicado: (2008)

Expression of IL-20 in synovium and lesional skin of patients with psoriatic arthritis: differential response to alefacept treatment
por: Lebre, Maria C, et al.
Publicado: (2012)

Synovial Tissue Response to Treatment in Rheumatoid Arthritis
por: Vieira-Sousa, Elsa, et al.
Publicado: (2011)

Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy: arrest of bone loss
por: Wijbrandts, C A, et al.
Publicado: (2008)

TWEAK and its receptor Fn14 in the synovium of patients with rheumatoid arthritis compared to psoriatic arthritis and its response to tumour necrosis factor blockade
por: van Kuijk, A W R, et al.
Publicado: (2009)

Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions
por: Van den Bosch, F, et al.
Publicado: (2010)

Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial
por: van der Heijde, D, et al.
Publicado: (2008)

The prolactin receptor is expressed in rheumatoid arthritis and psoriatic arthritis synovial tissue and contributes to macrophage activation
por: Tang, Man Wai, et al.
Publicado: (2016)

Reliability of computerized image analysis for the evaluation of serial synovial biopsies in randomized controlled trials in rheumatoid arthritis
por: Haringman, Jasper J, et al.
Publicado: (2005)

Treatment-specific changes in circulating adipocytokines: a comparison between tumour necrosis factor blockade and glucocorticoid treatment for rheumatoid arthritis
por: Klaasen, R., et al.
Publicado: (2012)

Synovial Tissue Response to Treatment in Psoriatic Arthritis
por: Codullo, Veronica, et al.
Publicado: (2011)

Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases
por: Burmester, G R, et al.
Publicado: (2009)

Surprising negative association between IgG1 allotype disparity and anti-adalimumab formation: a cohort study
por: Bartelds, Geertje M, et al.
Publicado: (2010)

Distinct synovial immunopathology in Behçet disease and psoriatic arthritis
por: Cañete, Juan D, et al.
Publicado: (2009)

Long-term treatment with adalimumab in psoriatic arthritis: serum adalimumab concentration, immunogenicity and the link with clinical response
por: Chimenti, Maria Sole, et al.
Publicado: (2016)

Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor
por: Kavanaugh, Arthur, et al.
Publicado: (2014)

Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease
por: Burmester, Gerd R, et al.
Publicado: (2013)

Effectiveness of Adalimumab for the Treatment of Psoriatic Arthritis: An Italian Real-Life Retrospective Study
por: D'Angelo, Salvatore, et al.
Publicado: (2019)

Insight into the Endocrine System and the Immune System: A Review of the Inflammatory Role of Prolactin in Rheumatoid Arthritis and Psoriatic Arthritis
por: Tang, Man W., et al.
Publicado: (2017)

Influenza H1N1 infection in a patient with psoriatic arthritis in treatment with Adalimumab: a case report
por: Serrato, Varlei A., et al.
Publicado: (2010)

Monocyte migration to the synovium in rheumatoid arthritis patients treated with adalimumab
por: Herenius, M M J, et al.
Publicado: (2011)

Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo
por: Gladman, Dafna D., et al.
Publicado: (2022)

Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1
por: Mease, Philip J, et al.
Publicado: (2017)

Synovitis in Psoriatic Arthritis: Immunohistochemistry, Comparisons With Rheumatoid Arthritis, and Effects of Therapy
por: van Kuijk, Arno W. R., et al.
Publicado: (2011)

The influence of adalimumab treatment on the systemic gene expression in patients with psoriatic arthritis – preliminary report
por: Krawczyk, Agata, et al.
Publicado: (2021)

Treatment patterns with etanercept and adalimumab for psoriatic diseases in a real-world setting
por: Bonafede, Machaon, et al.
Publicado: (2013)

Comparative Effectiveness of Adalimumab versus Secukinumab for the Treatment of Psoriatic Arthritis: A Matching-Adjusted Indirect Comparison
por: Strand, Vibeke, et al.
Publicado: (2017)

From Synovial Tissue to Peripheral Blood: Myeloid Related Protein 8/14 Is a Sensitive Biomarker for Effective Treatment in Early Drug Development in Patients with Rheumatoid Arthritis
por: Choi, Ivy Y., et al.
Publicado: (2014)

Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1)
por: Sieper, Joachim, et al.
Publicado: (2013)

Comorbidity burden in the first three years after diagnosis in patients with rheumatoid arthritis, psoriatic arthritis or spondyloarthritis: a general practice registry-based study
por: Stouten, Veerle, et al.
Publicado: (2021)

Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study
por: Keystone, Edward C, et al.
Publicado: (2017)

Eruptive lentiginosis confined to areas of regressing psoriatic plaques after adalimumab treatment()()
por: Garcia-Souto, Fernando
Publicado: (2021)

Cost per Responder Analysis of Secukinumab versus Adalimumab in the Treatment of Psoriatic Disease
por: Gisondi, Paolo, et al.
Publicado: (2022)

Psoriatic Arthritis That Responded Dramatically When Infliximab Was Switched to Adalimumab
por: Ohshima, Yuichiro, et al.
Publicado: (2013)

Treatment recommendations for psoriatic arthritis
por: Ritchlin, C T, et al.
Publicado: (2009)

Trends in psoriatic arthritis epidemiology in Poland
por: Tłustochowicz, Małgorzata, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_d7jfiblt4jl73l6i90tk2svj3m